41:I[185,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"SendEmailButton"] 43:I[63625,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"AddToLibraryButton"] 44:I[29721,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"ShareButton"] 45:I[58016,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"ProcessEpisodeButton"] 46:I[45269,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"SignupCTA"] 3a:["$","h1",null,{"className":"max-w-[22ch] font-display text-[clamp(32px,4.5vw,48px)] font-medium leading-[1.05] tracking-[-0.02em] text-[color:var(--fg-1)] text-balance","children":"Week in Diabetes & Endocrinology (May 4, 2026): AID in Pregnancy, Tirzepatide ICERs, AACE Signals, Dapagliflozin & Anemia, Hypoglycemia Models, Oat Diet Trial"}] 3b:["$","div",null,{"className":"flex flex-wrap items-center gap-x-4 gap-y-1 font-mono text-[12px] uppercase tracking-[0.1em] text-[color:var(--fg-3)]","children":[["$","time",null,{"dateTime":"2026-05-05T18:09:08.000Z","children":"May 5, 2026"}],["$","span",null,{"aria-hidden":true,"children":"·"}],["$","span",null,{"children":"00:15:56"}],false]}] 42:T478,

This episode reviews key diabetes/endocrinology updates for the week ending May 1, 2026: FDA clearance of Tandem Control-IQ Plus automated insulin delivery for pregnancy in type 1 diabetes supported by the CIRCUIT trial showing improved pregnancy-specific time-in-range; a US cost-effectiveness analysis in type 2 diabetes finding tirzepatide 10 mg and 15 mg cost-effective vs semaglutide 2 mg (ICERs ≈$70,147 and ≈$54,699 per QALY); late-breaking AACE meeting signals across obesity (combination therapies), thyroid ultrasound findings, and access disparities; a meta-analysis showing dapagliflozin increases hemoglobin in CKD; why most hypoglycemia risk prediction models in type 2 diabetes aren’t clinic-ready; and a trial where a short calorie-restricted high-dose oat diet lowered zonulin and increased butyric acid in metabolic syndrome.

00:00 Weekly Overview

01:07 FDA AID Pregnancy

04:14 Tirzepatide Value Math

06:39 AACE Meeting Signals

08:48 SGLT2 Anemia Boost

11:23 Hypoglycemia Prediction Reality

13:16 Oats Gut Barrier Pearl

15:29 Wrap Up and Notes